Mphasis Full Year 2025 Earnings: In Line With Expectations

Mphasis (NSE:MPHASIS) Full Year 2025 Results

Key Financial Results

• Revenue: ₹142.3b (up 7.2% from FY 2024).
• Net income: ₹17.0b (up 9.5% from FY 2024).
• Profit margin: 12% (in line with FY 2024).
• EPS: ₹89.88 (up from ₹82.42 in FY 2024).

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Mphasis Meets Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) was also in line with analyst expectations.

The primary driver behind last 12 months revenue was the Banking and Financial Services segment contributing a total revenue of ₹69.1b (49% of total revenue). Notably, cost of sales worth ₹81.6b amounted to 57% of total revenue thereby underscoring the impact on earnings.Explore how MPHASIS's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 8.8% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the IT industry in India.

Performance of the Indian IT industry.

The company's shares are up 2.9% from a week ago.

Risk Analysis

You still need to take note of risks, for example - Mphasis has 1 warning sign we think you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.